CAPABILITIES IN THE INNOVATION OF SMALL MOLECULE DRUG DISCOVERY AND DEVELOPMENT
PipelineBased on its Affinity Detection by Mass Spectroscopy (ADMS) platform, Keythera Biopharmaceuticals develops a drug pipeline centered on first-in-class therapeutics, targeting major disease areas with urgent unmet clinical needs. The company's current R&D achievements comprise six novel drug candidates: two currently in Phase I clinical trials, one in Phase II, one progressing through Investigational New Drug (IND) application, and two at the Preclinical Candidate Compound (PCC) proof-of-concept stage.
TechnologyKeythera Biopharmaceuticals specializes in utilizing an advanced screening platform called Affinity Detection by Mass Spectroscopy (ADMS), which is based on affinity-based high throughput screening technology. This cutting-edge platform allows for the screening of up to 250,000 compounds per day on each ADMS workstation. ADMS integrates various technologies, including bioinformatics, chemical informatics, structural chemistry, computer-aided drug design, and combinatorial chemistry.
By serving as an intelligent platform for drug screening and optimization, ADMS significantly expedites the discovery of innovative small molecule drugs while mitigating the risks associated with new drug development. It plays a crucial role in the development of new drugs with clinical differentiation. One key advantage of ADMS is its incorporation of artificial intelligence, which overcomes the limitations of other AI-assisted drug development technologies by enabling rapid validation through the acquisition of experimental data.
Keythera Biopharmaceuticals was established by a team of proficient scientists hailing from the United States, possessing extensive knowledge in the realms of drug discovery and development research. Their collective expertise spans across various domains, including preclinical and clinical development, positioning them as frontrunners in the field. Moreover, they possess world-class original innovation capabilities specifically in the realm of small molecule drug research and development, which have yielded comprehensive and successful outcomes.
Throughout its existence, the company has consistently maintained a workforce comprised of individuals with exceptional educational backgrounds, with each member holding a Bachelor's degree or higher. Notably, 57% of employees have attained a Master's degree, while an additional 19% possess a Doctorate degree. The research and development division, encompassing 85.71% of the personnel, exclusively consists of graduates from renowned universities, boasting remarkable expertise in their respective fields. Keythera Biopharmaceuticals is committed to advancing novel therapies to effectively address unmet medical needs both within China and on a global scale.
0512-63020039
Unit B2-508, Bio-Bay, 218 Xinghu Street, SIP, Suzhou, Jiangsu, China
蘇公網(wǎng)安備32059002005508號
